

## APPENDIX IV

## STATUTORY AND GENERAL INFORMATION

### A. FURTHER INFORMATION ABOUT OUR GROUP

#### 1. Incorporation of our Company

Our Company was initially established in the PRC as a limited company on 20 May 2014 under the name of Suzhou Qin hao Pharmaceutical Research and Development Co., Ltd. (蘇州勤浩藥物研究開發有限公司), and subsequently changed our name to Qin hao Pharmaceutical (Suzhou) Co., Ltd. (勤浩醫藥(蘇州)有限公司). On 3 July 2025, our Company was converted into a joint stock company with limited liability. Upon completion, our Company was renamed as Suzhou Genhouse Bio Co., Ltd. (勤浩醫藥(蘇州)股份有限公司) with registered capital of RMB14,700,000. As of the date of this document, the registered capital of our Company was RMB17,584,095. Our registered address is located at China (Jiangsu) Pilot Free Trade Zone Suzhou Area, Suzhou Industrial Park, No. 1 Xinze Road, Biomedical Industrial Park Phase III, Block A, Building 8, Unit 401, Suzhou, Jiangsu Province, China.

Our principal place of business in Hong Kong is located at 31/F, Tower Two, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong. Dr. Wang and Mr. Chow Tsz Ho (周梓浩先生) have been appointed as the authorised representatives of our Company for the acceptance of service of process in Hong Kong whose correspondence address is the same as our principal place of business in Hong Kong.

As our Company was established in the PRC, our operation, corporate structure and Articles of Association are subject to the relevant laws and regulations in the PRC. See “Appendix III — Summary of our Articles of Association”. See “Regulatory Overview” for the summary of certain relevant aspects of the laws and regulations of the PRC.

#### 2. Changes in Share Capital

Our Company was established as a limited liability company in the PRC on 20 May 2014 with an initial registered capital of RMB1,000,000 and was converted into a joint stock company with limited liability on 3 July 2025 under the PRC laws. As of the date of this document, the number of our total issued Shares was 17,584,095.

Our Company experienced a total of ten registered capital increases from February 2015 to January 2026. Through these rounds, our registered capital increased from RMB1,000,000 to RMB17,584,095.

Save as disclosed in “History, Development and Corporate Structure”, there has been no alteration in the share capital of our Company within two years immediately preceding the date of this document.

#### 3. Resolutions of our Shareholders in relation to the [REDACTED]

At the general meeting of our Shareholders held on 13 January 2026, the following resolutions, among other things, were duly passed:

- (a) the issue by our Company of H Shares with a nominal value of RMB0.1 each and such H Shares be [REDACTED] on the [REDACTED]. In this connection, the sub-division of our Shares with nominal value of RMB1.0 each on the basis of 1:10, effective immediately prior to the [REDACTED], and taking into account the Share Subdivision, the issue of H Shares of nominal value of RMB0.1 each and such H Shares be [REDACTED] on the [REDACTED];
- (b) the number of H shares to be issued shall be no more than 25% of the total issued share capital of our Company as enlarged by the [REDACTED] before the exercise of the [REDACTED], and the grant of the [REDACTED] in respect of no more than 15% of the number of H Shares issued pursuant to the [REDACTED];
- (c) subject to the CSRC’s approval, upon completion of the [REDACTED], [REDACTED] Unlisted Shares will be converted into H Shares on a one-for-one basis; and
- (d) authorisation of our Board or the duly authorised individual(s) to handle all matters relating to, among other things, the [REDACTED], the issue and the [REDACTED] of H Shares on the Stock Exchange.

## APPENDIX IV

## STATUTORY AND GENERAL INFORMATION

Pursuant to the resolutions passed at a duly convened general meeting of our Shareholders on 13 January 2026, among other matters, our Articles was further amended, approved and adopted and shall become effective upon the [REDACTED].

### 4. Changes in the Registered Capital of our Subsidiaries

A summary of the corporate information and the particulars of our subsidiaries are set out in “History, Development and Corporate Structure” and Note 1 to the Accountant’s Report as set out in Appendix I to this document.

Genhouse Yancheng was established under the laws of the PRC as a limited liability company on 7 November 2025, with an initial share capital of RMB100 million. Save as disclosed above, there has been no alteration in the registered capital of any of our subsidiaries within the two years immediately preceding the date of this document.

## B. FURTHER INFORMATION ABOUT OUR BUSINESS

### 1. Summary of Material Contracts

The following contracts (not being contracts entered into in the ordinary course of business) have been entered into by members of our Group within the two years preceding the date of this document and are or may be material:

- (a) On 27 December 2024, we entered into a working capital loan agreement with Industrial Bank Co., Ltd. Suzhou Branch (興業銀行股份有限公司蘇州分行), with aggregate loan amounting to RMB5.0 million. Dr. Wang and his spouse Ms. Lu Qin were the named guarantors in respect of this loan. The said Ms. Lu is the spouse of Dr. Wang.
- (b) On 6 January 2025, we entered into a working capital loan agreement with China Everbright Bank Co., Ltd. Suzhou Branch (中國光大銀行股份有限公司蘇州分行), with aggregate loan amounting to RMB5.0 million. Dr. Wang and his spouse Ms. Lu Qin were the named guarantors in respect of this loan.
- (c) On 8 September 2025, we entered into a working capital loan agreement with Jiangsu Suzhou Rural Commercial Bank Co., Ltd. (Technology Finance Industrial Park Sub-branch) (江蘇蘇州農村商業銀行股份有限公司(科技金融產業園支行)), with aggregate loan amounting to RMB5.0 million. Dr. Wang and his wife Ms. Lu Qin were the named guarantors in respect of this loan.
- (d) On 29 October 2025, we entered into an investment agreement with Jiangsu Binhai Economic Development Zone Management Committee (江蘇濱海經濟開發區管理委員會) in connection with our Targeted Anti-tumour Innovative Drug — Clinical and Commercial Production Base Project (靶向抗腫瘤創新藥 — 臨床及商業化生產基地項目).
- (e) On 30 January 2026, we entered into an unsecured working capital loan agreement with Agricultural Bank of China Limited, Suzhou Industrial Park Sub-branch (中國農業銀行股份有限公司蘇州工業園區支行), with aggregate loan amounting to RMB10.0 million.
- (f) On 12 June 2026, we entered into an unsecured working capital loan agreement with Shanghai Pudong Development Bank Co., Ltd., Suzhou Branch (上海浦東發展銀行股份有限公司蘇州分行), with aggregate loan amounting to RMB10.0 million.
- (g) [the [REDACTED]].
- (h) [the cornerstone investment agreements].

## APPENDIX IV

## STATUTORY AND GENERAL INFORMATION

### 2. Our Material Intellectual Property Rights

#### (a) Trademarks

As of the Latest Practicable Date, we had registered the following trademarks which we consider to be material to our business:

| No. | Trademark                                                                         | Jurisdiction | Registered owner | Class | Registration number | Expiry date      |
|-----|-----------------------------------------------------------------------------------|--------------|------------------|-------|---------------------|------------------|
| 1.  |  | China        | Our Company      | 5     | 66359397            | 20 January 2033  |
| 2.  |  | China        | Our Company      | 35    | 66356590            | 20 January 2033  |
| 3.  |  | China        | Our Company      | 5     | 66352089            | 27 March 2033    |
| 4.  |  | China        | Our Company      | 5     | 66356138            | 27 January 2033  |
| 5.  |  | China        | Our Company      | 5     | 44839320            | 20 February 2031 |
| 6.  |  | China        | Our Company      | 5     | 44850170            | 6 April 2031     |
| 7.  |  | Hong Kong    | Our Company      | 5     | 306737545           | 25 November 2034 |

#### (b) Patents

As of the Latest Practicable Date, we had registered the following patents which we consider to be material to our business:

| No. | Patent Title                                                                                  | Patent Type      | Patent Owner | Jurisdiction | Patent number    | Application date |
|-----|-----------------------------------------------------------------------------------------------|------------------|--------------|--------------|------------------|------------------|
| 1.  | Pyrazine derivative and application thereof in inhibiting SHP2 (吡嗪類衍生物及其在抑制SHP2中的應用). . . . . | Invention Patent | Our Company  | China        | ZL201910160960.7 | 4 March 2019     |
| 2.  | Pyrazine derivative and application thereof in inhibiting SHP2 (吡嗪類衍生物及其在抑制SHP2中的應用). . . . . | Invention Patent | Our Company  | China        | ZL202080014053.2 | 2 March 2020     |
| 3.  | Compounds containing benzosultam (含苯基並內磺醯胺的化合物). . . . .                                      | Invention Patent | Our Company  | China        | ZL202180030966.8 | 26 April 2021    |

#### (c) Domain names

As of the Latest Practicable Date, we owned the following domain name which we consider to be material to our business:

| No. | Domain name               | Registered owner | Registration date | Expiry date      |
|-----|---------------------------|------------------|-------------------|------------------|
| 1.  | genhousebio.com . . . . . | Our Company      | 14 December 2015  | 14 December 2031 |

Save as aforesaid, as of the Latest Practicable Date, there were no other trade or service marks, patents, intellectual or industrial property rights which were material in relation to our business.

## APPENDIX IV

## STATUTORY AND GENERAL INFORMATION

### C. FURTHER INFORMATION ABOUT OUR DIRECTORS AND SENIOR MANAGEMENT

#### 1. Particulars of the Service Contracts

Each of our Directors entered into a service contract or appointment letter with our Company. The principal particulars of these service contracts and appointment letters comprise (i) the scope of confidential information; (ii) job description; (iii) labour discipline and professional ethics. The service contracts and appointment letters may be renewed in accordance with our Articles and the applicable laws, rules and regulations.

Save as disclosed above, none of our Directors or Senior managements has entered into any service contracts as a Director or Senior management with any member of our Group (excluding contracts expiring or determinable by the employer within one year without payment of compensation (other than statutory compensation)).

#### 2. Remuneration of Directors

Our Directors receive remuneration in the forms of salaries, allowances and benefits in kind, discretionary bonuses, and retirement scheme contributions. For details of the remuneration of our Directors, see “Directors and Senior Management — Directors’ Remuneration”. Save as disclosed therein, none of our Directors received other remunerations or benefits in kind from us.

For the years ended 31 December 2024 and 2025, and the five months ended 31 May 2026, the five highest paid individuals of our Group included two, three and three Directors, and the aggregate amount of salaries, allowance, and benefits-in-kind, discretionary bonuses, retirement scheme contributions and share-based payment expenses to the highest paid individuals who are neither Directors nor chief executives of our Company were RMB6.6 million, RMB4.5 million and RMB13.2 million, respectively.

During the Track Record Period, no fees were paid by our Group to any of our Directors, the five highest paid individuals as an inducement to join us or as compensation for loss of office.

### D. [REDACTED] SHARE INCENTIVE SCHEME

The following is a summary of the principal terms of the [REDACTED] Share Incentive Scheme, which was approved and adopted by the Board on 6 January 2026. The terms of the [REDACTED] Share Incentive Scheme is not subject to the provisions of Chapter 17 of the [REDACTED] Rules pursuant to Rule 17.02(1)(b) of the [REDACTED] Rules as no further options or awards will be granted under the [REDACTED] Share Incentive Scheme after the [REDACTED]. We shall re-comply with Chapter 17 of the [REDACTED] Rules in the event of any material amendment to our [REDACTED] Share Incentive Scheme. Our [REDACTED] Share Incentive Platform will not cause any dilution of the shareholding of our Shareholders after the [REDACTED] given all underlying Shares granted have been issued to the relevant Participants.

#### Eligible Participants

Qianqin Technology LP was established as our [REDACTED] Share Incentive Platform in recognition of the contributions of our senior management and employees, and to incentivise them to further promote our development. The Participants of our [REDACTED] Share Incentive Scheme shall be given partnership interests in our Qianqin Technology LP, which is subject to approvals by our Board.

#### Grant of Share Awards

Each Participant will be granted restricted shares in the form of economic interest in Qianqin Technology LP as a partner (“Share Awards”). Upon becoming the partner of Qianqin Technology LP, the Participant indirectly receives economic interest in the number of Shares underlying the Share Awards granted to the Participant held by Qianqin Technology LP.

## APPENDIX IV

## STATUTORY AND GENERAL INFORMATION

### Payment of the Price of the Share Awards

The Participants must subscribe for the Share Awards with self-financed funds, or as the case might be. The grant price of the Share Awards shall be determined by the Administrator, who may determine the price with reference to our valuation, or by other means of valuation, and may apply a certain discount. Generally, Participants shall make the corresponding payment for Share Awards in entirety and in a timely manner.

### Administration of Qianqin Technology LP

Pursuant to the terms of the [REDACTED] Share Incentive Scheme, our Board shall act as the administrator (“Administrator”) of the [REDACTED] Share Incentive Scheme, and shall be responsible for, among others, (i) determining the price of the Share Awards; (ii) determining the Participants from time to time according to their contributions to our Group; (iii) determining the number of Share Awards to be granted to the Participants; (iv) arranging the Participants to execute the grant agreement, Qianqin Technology LP partnership agreement and other ancillary documents; (v) determining and amending the terms and conditions of the Share Awards; and (vi) other matters that the Administrator shall be responsible for under the [REDACTED] Share Incentive Scheme. For the avoidance of doubt, the management and control of Qianqin Technology LP, our [REDACTED] Share Incentive Platform, vests in Dr. Wang as its general partner. See “History, Development and Corporate Structure — [REDACTED] Share Incentive Platform”.

### Restrictions of Transfer

Subject to the relevant laws, regulations, normative documents, and the requirements of the CSRC and unless otherwise indicated, the Share Awards granted to the Participants shall not be transferred, pledged, contributed, or otherwise disposed of in any form, before the [REDACTED], and/or within one year after the [REDACTED].

### Rights Attached to the Share Awards

Dr. Wang, the general partner of Qianqin Technology LP, shall exercise voting rights on behalf of the eligible Participants in respect of the Shares underlying the Share Awards.

### Details of the Participants

The following table set out the details of the partnership structure of Qianqin Technology LP.

| No.                    | Name of the partner         | Amount of subscription | % of the total shares in Qianqin Technology LP |
|------------------------|-----------------------------|------------------------|------------------------------------------------|
|                        |                             | (RMB)                  | (%)                                            |
| 1.                     | Dr. Wang . . . . .          | 49,950                 | 75.96                                          |
| 2.                     | Wang Xiaofeng . . . . .     | 50                     | 0.08                                           |
| 3.                     | Mike Liu . . . . .          | 4,398.72               | 6.69                                           |
| 4.                     | Li Jiapeng . . . . .        | 2,932.48               | 4.46                                           |
| 5.                     | Dr. Zhang Guiping . . . . . | 2,932.48               | 4.46                                           |
| 6.                     | Liu Guidong . . . . .       | 366.56                 | 0.56                                           |
| 7.                     | Tong Shuilong . . . . .     | 366.56                 | 0.56                                           |
| 8.                     | Ji Feihong . . . . .        | 366.56                 | 0.56                                           |
| 9.                     | Wang Haidan . . . . .       | 4,398.72               | 6.69                                           |
| <b>Total</b> . . . . . |                             | <b>65,762.08</b>       | <b>100.00</b>                                  |

## E. DISCLOSURE OF INTERESTS

### 1. Interests of our Directors

Save as disclosed below, immediately following the completion of the [REDACTED] (assuming that the [REDACTED] is not exercised and taking into account the Share Subdivision) and the conversion of the Unlisted Shares into H Shares, so far as our Directors are aware, none of our Directors will have any interest and/or short position (as applicable) in the Shares, underlying Shares or

## APPENDIX IV

## STATUTORY AND GENERAL INFORMATION

debentures of our Company or our associated corporation (within the meaning of Part XV of the SFO) which will be required to be notified to our Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they are taken or deemed to have under such provisions of the SFO) or which will be required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein, or which will be required, pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules to be notified to our Company and the Stock Exchange, once the H Shares are [REDACTED] on the Stock Exchange.

| Name of Director        | Position                        | Nature of Interest                                     | Number of Shares | Class of shares | Approximate percentage of interest in our Company immediately after the [REDACTED] |
|-------------------------|---------------------------------|--------------------------------------------------------|------------------|-----------------|------------------------------------------------------------------------------------|
| Dr. Wang . . . . .      | Chairman and executive Director | Beneficiary interest                                   | 32,749,800       | H Shares        | [REDACTED]                                                                         |
|                         |                                 | Interest in controlled entity (Ruihao Technology LP)   | 15,923,780       | H Shares        | [REDACTED]                                                                         |
|                         |                                 | Interest in controlled entity (Kaihao Technology LP)   | 11,208,310       | H Shares        | [REDACTED]                                                                         |
|                         |                                 | Interest in controlled entity (Qianqin Technology LP)  | 8,377,530        | H Shares        | [REDACTED]                                                                         |
|                         |                                 | Interest in controlled entity (Haosheng Technology LP) | 2,147,820        | H Shares        | [REDACTED]                                                                         |
| Dr. Zhang Guiping . . . | Executive Director              | Interest in controlled entity (Kaihao Technology LP)   | 11,208,310       | H Shares        | [REDACTED]                                                                         |

### 2. Interests of Substantial Shareholders

For information on the persons who will, immediately following the completion of the [REDACTED] without taking into account any Shares which may be issued pursuant to the exercise of the [REDACTED], have interests or short positions in our Shares or underlying Shares which would be required to be disclosed to us and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or who will directly and/or indirectly, be interested in 10% or more of the nominal value of any class of share capital carrying the rights to vote in all circumstances at general meetings of our Company, see “Substantial Shareholders”.

Save as disclosed in “Substantial Shareholders”, our Directors and the chief executive (or equivalent) of our Company are not aware of any other person (other than our Directors) who will, immediately following the completion of the [REDACTED] (assuming no exercise of the [REDACTED]) and the conversion of the Domestic Shares into H Shares, have an interest and/or short position in the Shares or underlying Shares which would fall to be disclosed to our Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or who is, directly or indirectly, interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of our Company.

## APPENDIX IV

## STATUTORY AND GENERAL INFORMATION

### *Disclaimers*

Save as disclosed in “History, Development and Corporate Structure,” none of our Directors, nor any of the experts referred to in “— Other Information — Qualifications and Consents of Experts” below has any direct or indirect interest in the promotion of, or in any assets which have been, within the two years immediately preceding the date of this document, acquired or disposed of by, or leased to, any member of our Group, or are proposed to be acquired or disposed of by, or leased to, any member of our Group nor will any Director apply for [REDACTED] either in his/her own name or in the name of a nominee; or materially interested in any contract or arrangement subsisting at the date of this document which is significant in relation to our business.

Save in connection with the [REDACTED], none of our Directors nor any of the experts referred to in “— Other Information — Qualifications and Consents of Experts” below, is materially interested in any contract or arrangement subsisting at the date of this document which is significant in relation to the business of our Group.

No cash, securities or other benefit has been paid, allotted or given within the two years preceding the date of this document to any promoter of our Company nor is any such cash securities or benefit intended to be paid, allotted or given on the basis of the [REDACTED] or related transactions as mentioned.

None of our Directors knows of any person (not being a Director of our Company) who will, immediately following completion of the [REDACTED], have an interest or short position in the Shares or underlying Shares of our Company which would fall to be disclosed to our Company under the provisions of Divisions 2 and 3 of Part XV of SFO or be interested, directly or indirectly, in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of any member of our Group.

Save as disclosed in “Business”, none of our Directors or their respective close associates (as defined under the Listing Rules) or the existing Shareholders (who, to the knowledge of our Directors, owns more than 5% of our issued share capital of our Company) has any interests in our five largest customers or suppliers in each year during the Track Record Period.

### **F. OTHER INFORMATION**

#### **1. Estate Duty**

Our Directors have been advised that no material liability for estate duty is likely to fall on our Group in Hong Kong and the PRC.

#### **2. Litigation**

So far as our Directors are aware, no litigation, arbitration or claim of material importance is pending or threatened against any member of our Group that could have a material adverse effect on our financial condition or results of operations as of the Latest Practicable Date.

#### **3. Sole Sponsor**

The Sole Sponsor has made an application on behalf of our Company to the [REDACTED] Committee of the Stock Exchange for the [REDACTED] of, and permission to deal in, the H Shares of our Company. All necessary arrangements have been made to enable the securities to be admitted into [REDACTED].

As of the Latest Practicable Date, Huatai Financial Holdings (Hong Kong) Limited held less than 5% of the total issued share capital of our Company. Therefore, the Sole Sponsor satisfies the independence criteria applicable to sponsor as set out in Rule 3A.07 of the Listing Rules. The Sole Sponsor will receive a fee of HK\$7.84 million for acting as sponsor for the [REDACTED].

## APPENDIX IV

## STATUTORY AND GENERAL INFORMATION

### 4. Qualifications and Consents of Experts

The following experts have each given and have not withdrawn their respective written consents to the issue of this document with copies of their reports, letters, opinions or summaries of opinions (as the case may be) and the references to their names included herein in the form and context in which they are respectively included.

| Name                                          | Qualification(s)                                                                                                                                                                                                                                                                                                                                            |
|-----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Huatai Financial Holdings (Hong Kong) Limited | A licenced corporation under the SFO to conduct Type 1 (dealing in securities), Type 2 (dealing in futures contracts), Type 3 (leveraged foreign exchange trading), Type 4 (advising on securities), Type 6 (advising on corporate finance), Type 7 (providing automated trading services) and Type 9 (asset management) regulated activities under the SFO |
| Ernst & Young                                 | Certified Public Accountants and Registered Public Interest Entity Auditor                                                                                                                                                                                                                                                                                  |
| Jingtian & Gongcheng                          | Legal advisers to our Company as to PRC laws                                                                                                                                                                                                                                                                                                                |
| Jingtian & Gongcheng                          | Legal advisers to our Company as to intellectual property laws                                                                                                                                                                                                                                                                                              |
| Allbright                                     | Legal advisers to our Company as to data laws                                                                                                                                                                                                                                                                                                               |
| China Insights Industry Consultancy Limited   | Independent industry consultant                                                                                                                                                                                                                                                                                                                             |

As of the Latest Practicable Date, none of the experts named above had any shareholding interests in our Company or any of our subsidiaries or the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of our Group.

### 5. Binding Effect

This document shall have the effect, if an application is made in pursuance hereof, of rendering all persons concerned bound by all the provisions (other than the penal provisions) of sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance so far as applicable.

### 6. Bilingual Document

The English language and Chinese language versions of this document are being published separately in reliance upon the exemption provided by section 4 of the Companies Ordinance (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).

### 7. Promoters

The promoters as of the time of the conversion of our Company into a joint stock company are set out below:

|          | Promoter Name             |
|----------|---------------------------|
| 1. . . . | Dr. Wang                  |
| 2. . . . | Ruihao Technology LP      |
| 3. . . . | Kaihao Technology LP      |
| 4. . . . | Qianqin Technology LP     |
| 5. . . . | Lingzheng Venture Capital |
| 6. . . . | Shanghai Shengyu Heike    |

## APPENDIX IV

## STATUTORY AND GENERAL INFORMATION

|           | Promoter Name               |
|-----------|-----------------------------|
| 7. . . .  | Kefa Jinding                |
| 8. . . .  | Tuojin Venture Capital      |
| 9. . . .  | Hengbo Tongzhou             |
| 10. . . . | Suzhou Xingfan              |
| 11. . . . | Changtao Yueyin             |
| 12. . . . | Zhongke Dynamic Balance     |
| 13. . . . | Xingyi Venture Capital      |
| 14. . . . | Jiangsu Shengyu Heike       |
| 15. . . . | Jiuzhou Smart Medical       |
| 16. . . . | Qianhe Yafa                 |
| 17. . . . | Panyi Qin hao               |
| 18. . . . | Sanhua Hongdao              |
| 19. . . . | Weixuchen                   |
| 20. . . . | Jiangsu Hongtu              |
| 21. . . . | Changzhou Hongtu Talent     |
| 22. . . . | Shenzhen Capital (Xinjiang) |
| 23. . . . | Haosheng Technology LP      |
| 24. . . . | Kefa Xianghu                |
| 25. . . . | Shengshan Weichen           |
| 26. . . . | Yuanxing Xinyuan            |
| 27. . . . | Shenzhen Capital            |
| 28. . . . | Guohai Guochuang Qianjin    |
| 29. . . . | Guohai Zhongheng            |
| 30. . . . | Guohai No. 9                |
| 31. . . . | Yueyin Dingtai              |
| 32. . . . | Tuojin Zhonghe              |

Save as disclosed in this document, within the two years immediately preceding the date of this document, no cash, securities or benefit has been paid, allotted or given, or is proposed to be paid, allotted or given to the promoters named above in connection with the [REDACTED] or the related transactions described in this document.

### 8. Compliance Adviser

Our Company has appointed Red Solar Capital Limited as our compliance adviser in compliance with Rule 3A.19 of the Listing Rules.

## APPENDIX IV

## STATUTORY AND GENERAL INFORMATION

### 9. Preliminary Expenses

As of the Latest Practicable Date, we had not incurred material preliminary expenses.

### 10. Taxation of holders of H Shares

The sale, purchase and transfer of H Shares are subject to Hong Kong stamp duty if such sale, purchase and transfer are affected on the H Share register of members of our Company, including in circumstances where such transaction is affected on the Stock Exchange. The current rate charged on each of the purchaser and seller is 0.10% of the consideration or, if higher, the fair value of our H Shares being sold or transferred.

### 11. No Material Adverse Change

Our Directors confirm that there has been no material change in our financial or trading position since 31 May 2026 (being the date of the latest audited consolidated statements of financial position of our Group as set out in the Accountants’ Report in Appendix I to this document) and up to the date of this document.

### 12. Miscellaneous

- (a) Save as disclosed in this document:
  - (i) within the two years immediately preceding the date of this document, neither we nor any of our subsidiaries has issued or agreed to issue any share or loan capital;
  - (ii) no share or loan capital of our Company or any of our subsidiaries is under option or is agreed conditionally or unconditionally to be put under option; and
  - (iii) no commissions, discounts, brokerages or other special terms have been granted or agreed to be granted in connection with the issue or sale of any share or loan capital of our Company or any of our subsidiaries.
- (b) there are no founder, management or deferred shares nor any debentures in our Company or any of our subsidiaries have been issued or agreed to be issued;
- (c) no share or loan capital or debenture of our Company or any of our subsidiaries is under option or is agreed conditionally or unconditionally to be put under option;
- (d) no commissions, discounts, brokerages or other special terms have been granted in connection with the issue or sale of any share or loan capital of our Company or any of our subsidiaries;
- (e) none of our Directors have any interest, direct or indirect, in any assets which have been, within the two years immediately preceding the date of this document, acquired or disposed of by or leased to, any member of our Group, or are proposed to be acquired or disposed of by or leased to any member of our Group. Save as disclosed in this document, no equity or debt securities of any company within our Group is presently [REDACTED] on any [REDACTED] or traded on any trading system nor is any [REDACTED] or permission to deal being or proposed to be sought;
- (f) we have no outstanding convertible debt securities or debentures;
- (g) there is no arrangement under which future dividends are waived or agreed to be waived;
- (h) there are no procedures for the exercise of any right of pre-emption or transferability of subscription rights;
- (i) there has not been any interruption in the business of our Group which may have or has had a significant effect on the financial position of our Group in the 12 months preceding the date of this document; and
- (j) The English texts of this document shall prevail over their respective Chinese texts.